Method of plscr inhibition for cancer therapy
AssigneeErr-Cheng CHAN
InventorsErr-Cheng CHAN, Hong-Arh FAN, Kuei-Tien Chen, Yung-Bin Kuo, Jinn Shiun Chen, Chung-Wei Fan
Life of this patent
Estimating the term…
Abstract
The present invention relates to a method of using inhibitors of phospholipid scramblases (PLSCRs) for the prophylactic or therapeutic treatment of cancers. The PLSCR-inhibitors of the invention comprise compounds PLSCR-specific monoclonal antibodies, antagonists or nucleic acids, which have ability to decrease the level and/or biological activity of PLSCRs in cancer cells.
Claims25
A method for cancer therapy, which represses the activity of the wild type PLSCR family of proteins and the variants of PLSCR.
A pharmaceutical composition comprising a PLSCR-inhibitor and a pharmaceutically acceptable carrier, diluent or excipient.
Dependencies are inferred from the claim text.